- These are not official programs of the American College of Rheumatology.
- All industry sessions will be available on-demand on the virtual meeting platform until March 10, 2022.
Loading view.
Featured Lightning Talk
Why does remission in RA matter?
- Non-CME
- Host will take questions from noon - 12:30 p.m., Saturday, Nov. 6.
This program is developed and offered by AbbVie
Featured Lightning Talk
Psoriatic Arthritis: The role of imaging
- Non-CME
- Host will take questions from noon - 12:30 p.m., Saturday, Nov. 6.
This program is developed and offered by AbbVie
Featured Industry Session
Examine Taltz® (ixekizumab) injection 80mg/mL: A Review of Real-World Patient Cases
- Non-CME
This program is developed and offered by Lilly USA, LLC
Featured Industry Session
Explore the COSENTYX® (secukinumab) Evidence for Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
- Non-CME
This program is developed and offered by Novartis Pharmaceuticals Corporation
Featured Mini Session
Identifying Autoimmune Interstitial Lung Diseases: A Rheumatologist’s Perspective
- Non-CME
- Host will take questions from noon - 12:30 p.m., Sunday, Nov. 7.
This program is developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc.
Featured Industry Session
The Evolving Pathobiology of Axial Spondyloarthritis and Psoriatic Arthritis
- Non-CME
- Live Q&A
This program is developed and offered by UCB, INC
Featured Industry Session
Taltz® (ixekizumab) injection 80mg/mL Spotlight Session: 6 Clinical Trials Spanning 3 Indications
- Non-CME
This program is developed and offered by Lilly USA, LLC
Featured Industry Session
Taltz® (ixekizumab) injection 80mg/mL: A COAST-to-COAST Treatment
- Non-CME
This program is developed and offered by Lilly USA, LLC
Featured Industry Session
The Role of OFEV® (nintedanib) capsules: Insights for the Health Care Practitioner
- Non-CME
This program is developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc.